Drug discovery grants

PPP call for projects strengthening Pb-212 production/supply chain or enabling technologies for clinical application of Pb-212-based radiopharmaceuticals. Proposals must involve public-private collaboration and be submitted through KWF GMS; projects are embedded in a national TRT innovation network. Clinical trials and full therapeutic product development are out of scope.

PPP call for projects strengthening Pb-212 production/supply chain or enabling technologies for clinical application of Pb-212-based radiopharmaceuticals. Proposals must involve public-private collaboration with 40–60% industry co-funding, be submitted through KWF GMS, and align with Lead4Life governance and national TRT network. Clinical trials and full therapeutic product development are out of scope.

Supports investigator-initiated clinical trials (RCTs and other interventional studies) conducted by researchers at Swiss institutions. Clinical trial / RCT focus; patient-sample involvement expected.

Supports late-phase (phase 2/3) international clinical trials focused on radiotherapy or surgery as core experimental interventions for rare cancers (incidence <6/100,000/year) and/or hard-to-treat cancers (5-year survival <25%). Proposals must include partners from at least 3 of the 5 funding countries and demonstrate strong rationale for international collaboration, patient involvement, and quality-of-life assessment.

Supports late-phase (phase 2/3) international clinical trials focused on radiotherapy or surgery as core experimental interventions for rare cancers (incidence <6/100,000/year) and/or hard-to-treat cancers (5-year survival <25%). Requires partners from at least 3 of 5 funding countries; clinical-trial focus with mandatory patient involvement and quality-of-life assessment plans.

Open to researchers with an ongoing or recently finished KWF drug research project (start ≥6 months ago, end ≤1.5 years before 1 July 2026). Funds access to clinically relevant preclinical models, technologies and expertise (e.g. NAMs, PDX, organoids, CROs) to improve translational value. Dutch institutions only; commercial partner involvement requires a letter of intent.

Supports academic-led clinical trials (Phase I–III) for new investigational medicinal products targeting cancer with unmet medical needs. Lead institute must be in the Netherlands; public participating parties must be in Europe. Patient involvement required; public-private partnerships allowed. Proposals must be in English.

Add-on funding exclusively for ongoing or recently completed KWF projects to strengthen translational relevance of oncology drug development. Supports training, implementation, and validation of advanced preclinical models; outsourcing to academic service providers or CROs is allowed.

For mid-career researchers at UK universities, medical schools, hospitals or research institutions seeking to develop independent research programmes in cancer biology. Applicants must hold a salaried independent position funded by a Higher Education Funding Council, NHS or equivalent. Clinical trials, drug discovery as sole function, and early detection/prevention are excluded. Closed scheme requiring prior contact with CRUK before applying.

Open to researchers with a tenured or tenure-track position at Dutch universities, UMCs, KNAW/NWO institutes, and select other Dutch research organisations. Supports free and independent technology research with societal/scientific impact; requires a user committee of at least four knowledge users. Not intended for proposals predominantly focused on investments, contract research, or clinical trials.

Supports non-commercial, investigator-initiated cancer therapy trials (Investigator Initiated Trials). Applicants must submit a Part I short application; Part II is only submitted upon invitation by Deutsche Krebshilfe. Clinical trial focus with patient recruitment requirements; proposals must be in German.